StemRIM (4599.T)
JPY 298.0
(0.0%)
JPY 298.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | -44.34 Million JPY | -101.93% |
| 2023 | 2.3 Billion JPY | 9920.09% |
| 2022 | 22.97 Million JPY | -98.36% |
| 2021 | 1.4 Billion JPY | -33.33% |
| 2020 | 2.1 Billion JPY | 2000.0% |
| 2019 | 100 Million JPY | -50.0% |
| 2018 | 200 Million JPY | -33.33% |
| 2017 | 300 Million JPY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | -11.08 Million JPY | 0.13% |
| 2024 Q4 | -11.15 Million JPY | -0.6% |
| 2024 Q2 | -11.1 Million JPY | -0.92% |
| 2024 Q1 | -11 Million JPY | 54.54% |
| 2023 Q2 | -11.94 Million JPY | 0.0% |
| 2023 FY | 2.3 Billion JPY | 9920.09% |
| 2023 Q1 | -11.94 Million JPY | 2.55% |
| 2023 Q4 | -24.19 Million JPY | -101.03% |
| 2023 Q3 | 2.35 Billion JPY | 19776.8% |
| 2022 Q2 | -12.39 Million JPY | -216.83% |
| 2022 FY | 22.97 Million JPY | -98.36% |
| 2022 Q4 | -12.25 Million JPY | 1.6% |
| 2022 Q3 | -12.45 Million JPY | -0.45% |
| 2022 Q1 | 10.61 Million JPY | -99.11% |
| 2021 FY | 1.4 Billion JPY | -33.33% |
| 2021 Q4 | 1.19 Billion JPY | 1.17% |
| 2021 Q3 | 1.17 Billion JPY | 0.0% |
| 2021 Q2 | - JPY | -100.0% |
| 2021 Q1 | 210 Million JPY | -87.65% |
| 2020 FY | 2.1 Billion JPY | 2000.0% |
| 2020 Q4 | 1.7 Billion JPY | 0.0% |
| 2020 Q3 | 1.7 Billion JPY | 325.0% |
| 2020 Q2 | 400 Million JPY | 0.0% |
| 2020 Q1 | - JPY | 0.0% |
| 2019 FY | 100 Million JPY | -50.0% |
| 2019 Q4 | - JPY | 0.0% |
| 2018 FY | 200 Million JPY | -33.33% |
| 2017 FY | 300 Million JPY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.88 Billion JPY | 102.357% |
| PRISM BioLab Co.,LTD | 80.3 Million JPY | 155.225% |
| GNI Group Ltd. | 22.43 Billion JPY | 100.198% |
| Linical Co., Ltd. | 3.77 Billion JPY | 101.174% |
| Trans Genic Inc. | 2.24 Billion JPY | 101.972% |
| MEDINET Co., Ltd. | 98.25 Million JPY | 145.138% |
| Soiken Holdings Inc. | 2.48 Billion JPY | 101.787% |
| Cytori Cell Research Institute, Inc. | 1.29 Billion JPY | 103.431% |
| AnGes, Inc. | -3.06 Billion JPY | 98.553% |
| OncoTherapy Science, Inc. | -177.71 Million JPY | 75.045% |
| Nxera Pharma Co., Ltd. | 9.66 Billion JPY | 100.459% |
| Immuno-Biological Laboratories Co., Ltd. | 517.29 Million JPY | 108.573% |
| NanoCarrier Co., Ltd. | 110.95 Million JPY | 139.97% |
| Carna Biosciences, Inc. | 1.45 Billion JPY | 103.057% |
| CanBas Co., Ltd. | -984 Million JPY | 95.493% |
| D. Western Therapeutics Institute, Inc. | 391.69 Million JPY | 111.322% |
| RaQualia Pharma Inc. | 1.65 Billion JPY | 102.678% |
| Chiome Bioscience Inc. | 398.59 Million JPY | 111.126% |
| Kidswell Bio Corporation | 1.03 Billion JPY | 104.267% |
| PeptiDream Inc. | 17.21 Billion JPY | 100.258% |
| Oncolys BioPharma Inc. | 30.6 Million JPY | 244.908% |
| Ribomic Inc. | -10.5 Million JPY | -322.291% |
| SanBio Company Limited | -14.5 Million JPY | -205.771% |
| Healios K.K. | 108 Million JPY | 141.064% |
| BrightPath Biotherapeutics Co., Ltd. | -341 Thousand JPY | -12905.572% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -59.04 Million JPY | 24.891% |
| Delta-Fly Pharma, Inc. | -1.51 Million JPY | -2833.135% |
| CellSource Co., Ltd. | 3.18 Billion JPY | 101.392% |
| FunPep Company Limited | -680.28 Million JPY | 93.481% |
| Kringle Pharma, Inc. | 69.25 Million JPY | 164.042% |
| Stella Pharma Corporation | 217.29 Million JPY | 120.409% |
| TMS Co., Ltd. | -6.95 Million JPY | -538.115% |
| Noile-Immune Biotech Inc. | 314.56 Million JPY | 114.099% |
| Cuorips Inc. | 9.63 Million JPY | 560.482% |
| K Pharma,Inc. | 910 Million JPY | 104.874% |
| Takara Bio Inc. | 25.45 Billion JPY | 100.174% |
| ReproCELL Incorporated | 1.1 Billion JPY | 104.014% |
| PhoenixBio Co., Ltd. | 1.19 Billion JPY | 103.711% |
| StemCell Institute Inc. | 1.57 Billion JPY | 102.814% |
| Japan Tissue Engineering Co., Ltd. | 1.66 Billion JPY | 102.661% |
| CellSeed Inc. | 107.15 Million JPY | 141.388% |